# reload+after+2024-01-21 16:33:46.723311
address1§9605 Medical Center Drive
address2§Suite 270
city§Rockville
state§MD
zip§20850
country§United States
phone§301 417 4364
website§https://therivabio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
fullTimeEmployees§21
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Steven A. Shallcross CPA', 'age': 62, 'title': 'CEO, CFO, Treasurer, Corporate Secretary & Director', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 997674, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Vince  Wacher Ph.D.', 'title': 'Head of Product & Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael  Kaleko M.D., Ph.D.', 'title': 'Senior Vice President of Research & Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Ramon  Alemany Ph.D.', 'title': 'Senior VP of Discovery & Chairman of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lara M. Guzman', 'title': 'Senior Director of Project Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.509
currency§USD
dateShortInterest§1702598400
forwardEps§-1.01
exchange§ASE
quoteType§EQUITY
shortName§Theriva Biologics, Inc.
longName§Theriva Biologics, Inc.
firstTradeDateEpochUtc§1166452200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§044b9f48-1a7a-3d3f-9995-bb592e0e8b16
gmtOffSetMilliseconds§-18000000
targetHighPrice§7.0
targetLowPrice§2.0
targetMeanPrice§4.5
targetMedianPrice§4.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§3.744
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
